Literature DB >> 29500188

Metabolomics Profiles of Hepatocellular Carcinoma in a Korean Prospective Cohort: The Korean Cancer Prevention Study-II.

Sun Ha Jee1, Minjoo Kim2, Minkyung Kim2, Hye Jin Yoo3, Hyungyoon Kim3,4, Keum Ji Jung1, Seri Hong1, Jong Ho Lee5,3,4.   

Abstract

In the prospective Korean Cancer Prevention Study-II (KCPS-II), we investigated the application of metabolomics to differentiate subjects with incident hepatocellular carcinoma (HCC group) from subjects who remained free of cancer (control group) during a mean follow-up period of 7 years with the aim of identifying valuable metabolic biomarkers for HCC. We used baseline serum samples from 75 subjects with incident HCC and 134 age- and gender-matched cancer-free subjects. Serum metabolic profiles associated with HCC incidence were investigated via metabolomics analysis. Compared with the control group, the HCC group showed significantly higher serum levels of aspartate aminotransferase (AST), alanine aminotransferase, and γ-glutamyl transpeptidase. At baseline, compared with the control group, the HCC group showed significantly higher levels of 9 metabolites, including leucine, 5-hydroxyhexanoic acid, phenylalanine, tyrosine, arachidonic acid, and tauroursodeoxycholic acid (TUDCA), but lower levels of 28 metabolites, including oleamide, androsterone sulfate, L-palmitoylcarnitine, lysophosphatidic acid (LPA) 16:0, LPA 18:1, and lysophosphatidylcholines (lysoPC). Multiple linear regression revealed that the incidence of HCC was associated with the levels of tyrosine, AST, lysoPCs (16:1, 20:3), oleamide, 5-hydroxyhexanoic acid, androsterone sulfate, and TUDCA (adjusted R2 = 0.514, P = 0.036). This study showed the clinical relevance of the dysregulation of not only branched amino acids, aromatic amino acids, and lysoPCs but also bile acid biosynthesis and linoleic acid, arachidonic acid, and fatty acid metabolism. In addition, tyrosine, AST, lysoPCs (16:1, 20:3), oleamide, 5-hydroxyhexanoic acid, androsterone sulfate, and TUDCA were identified as independent variables associated with the incidence of HCC. Cancer Prev Res; 11(5); 303-12. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29500188     DOI: 10.1158/1940-6207.CAPR-17-0249

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  12 in total

1.  Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies.

Authors:  Jessica L Petrick; Andrea A Florio; Jill Koshiol; Ruth M Pfeiffer; Baiyu Yang; Kelly Yu; Chien-Jen Chen; Hwai-I Yang; Mei-Hsuan Lee; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2020-06-08       Impact factor: 7.316

Review 2.  Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.

Authors:  Serena De Matteis; Andrea Ragusa; Giorgia Marisi; Stefania De Domenico; Andrea Casadei Gardini; Massimiliano Bonafè; Anna Maria Giudetti
Journal:  Oxid Med Cell Longev       Date:  2018-11-04       Impact factor: 6.543

3.  Assessing the Effectiveness of Direct Data Merging Strategy in Long-Term and Large-Scale Pharmacometabonomics.

Authors:  Xuejiao Cui; Qingxia Yang; Bo Li; Jing Tang; Xiaoyu Zhang; Shuang Li; Fengcheng Li; Jie Hu; Yan Lou; Yunqing Qiu; Weiwei Xue; Feng Zhu
Journal:  Front Pharmacol       Date:  2019-02-20       Impact factor: 5.810

4.  Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case-control sets from EPIC.

Authors:  Julie A Schmidt; Georgina K Fensom; Sabina Rinaldi; Augustin Scalbert; Paul N Appleby; David Achaintre; Audrey Gicquiau; Marc J Gunter; Pietro Ferrari; Rudolf Kaaks; Tilman Kühn; Heiner Boeing; Antonia Trichopoulou; Anna Karakatsani; Eleni Peppa; Domenico Palli; Sabina Sieri; Rosario Tumino; Bas Bueno-de-Mesquita; Antonio Agudo; Maria-Jose Sánchez; María-Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; Aurora Perez-Cornago; Nada Assi; Elio Riboli; Konstantinos K Tsilidis; Timothy J Key; Ruth C Travis
Journal:  Int J Cancer       Date:  2019-04-29       Impact factor: 7.396

5.  Intestinal Candida albicans Promotes Hepatocarcinogenesis by Up-Regulating NLRP6.

Authors:  Zherui Liu; Yinyin Li; Chen Li; Guanglin Lei; Lin Zhou; Xiangling Chen; Xiaodong Jia; Yinying Lu
Journal:  Front Microbiol       Date:  2022-03-08       Impact factor: 5.640

6.  Discovery of plasma biomarkers for colorectal cancer diagnosis via untargeted and targeted quantitative metabolomics.

Authors:  Maoqing Wang; Zhiping Long; Weinan Xue; Chenghai Peng; Tianming Jiang; Jingshen Tian; Hongru Sun; Yu Gao; Yue Yu; Yanming Yu; Chen Gong; Fan Wang; Junde Zhou; Yashuang Zhao
Journal:  Clin Transl Med       Date:  2022-04

7.  Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study.

Authors:  Claire E Thomas; Hung N Luu; Renwei Wang; Guoxiang Xie; Jennifer Adams-Haduch; Aizhen Jin; Woon-Puay Koh; Wei Jia; Jaideep Behari; Jian-Min Yuan
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

8.  Metabolomic biomarkers for hepatocellular carcinoma: A systematic review.

Authors:  Ningning Feng; Fatao Yu; Feng Yu; Yuling Feng; Xiaolin Zhu; Zhihui Xie; Yi Zhai
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

9.  Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis.

Authors:  Lingling Wan; Qingyi Liu; Di Liang; Yongdong Guo; Guangjie Liu; Jinxia Ren; Yutong He; Baoen Shan
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

10.  Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma.

Authors:  José Luis Palacios-Ferrer; María Belén García-Ortega; María Gallardo-Gómez; María Ángel García; Caridad Díaz; Houria Boulaiz; Javier Valdivia; José Miguel Jurado; Francisco M Almazan-Fernandez; Salvador Arias-Santiago; Víctor Amezcua; Héctor Peinado; Francisca Vicente; José Pérez Del Palacio; Juan A Marchal
Journal:  Mol Oncol       Date:  2020-11-25       Impact factor: 7.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.